Arsanis Discontinues Ph II Trial of ASN100

Arsanis, Inc. (NASDAQ:ASNS) announced on 6/28/2018 the discontinuation of its Phase 2 clinical trial of ASN100 for the prevention of S. aureuspneumonia in high-risk, mechanically ventilated patients following the completion of a planned interim analysis of unblinded trial data by an independent data review committee (DRC).